Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium–Glucose Cotransporter-2 Inhibitors Versus Metformin

BACKGROUND Evidence on the risk for cardiovascular events associated with use of first-line sodium-glucose cotransporter-2 inhibitors (SGLT-2i) compared with metformin is limited. OBJECTIVE To assess cardiovascular outcomes among adults with type 2 diabetes (T2D) who initiated first-line treatment with SGLT-2i versus metformin. DESIGN Population-based cohort study. SETTING Claims data from 2 large U.S. commercial and Medicare databases (April 2013 to March 2020). PARTICIPANTS Patients with T2D aged 18 years and older (>65 years in Medicare) initiating treatment with SGLT-2i or metformin during April 2013 to March 2020, without any use of antidiabetic medications before cohort entry, were identified. After 1:2 propensity score matching in each database, pooled hazard ratios (HRs) and 95% CIs were reported. INTERVENTION First-line SGLT-2i (canagliflozin, empagliflozin, or dapagliflozin) or metformin. MEASUREMENTS Primary outcomes were a composite of hospitalization for myocardial infarction (MI), hospitalization for ischemic or hemorrhagic stroke or all-cause mortality (MI/stroke/mortality), and a composite of hospitalization for heart failure (HHF) or all-cause mortality (HHF/mortality). Safety outcomes including genital infections were assessed. RESULTS Among 8613 first-line SGLT-2i initiators matched to 17 226 metformin initiators, SGLT-2i initiators had a similar risk for MI/stroke/mortality (HR, 0.96; 95% CI, 0.77 to 1.19) and a lower risk for HHF/mortality (HR, 0.80; CI, 0.66 to 0.97) during a mean follow-up of 12 months. Initiators receiving SGLT-2i showed a lower risk for HHF (HR, 0.78; CI, 0.63 to 0.97), a numerically lower risk for MI (HR, 0.70; CI, 0.48 to 1.00), and similar risk for stroke, mortality, and MI/stroke/HHF/mortality compared with metformin. Initiators receiving SGLT-2i had a higher risk for genital infections (HR, 2.19; CI, 1.91 to 2.51) and otherwise similar safety as those receiving metformin. LIMITATION Treatment selection was not randomized. CONCLUSION As first-line T2D treatment, initiators receiving SGLT-2i showed a similar risk for MI/stroke/mortality, lower risk for HHF/mortality and HHF, and a similar safety profile except for an increased risk for genital infections compared with those receiving metformin. PRIMARY FUNDING SOURCE Brigham and Women's Hospital and Harvard Medical School.

[1]  S. Schneeweiss,et al.  Evolving channeling in prescribing SGLT‐2 inhibitors as first‐line treatment for type 2 diabetes , 2022, Pharmacoepidemiology and drug safety.

[2]  I. Hirsch,et al.  The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2021, Diabetologia.

[3]  C. Hung,et al.  The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials , 2021, Diabetologia.

[4]  J. Leksell,et al.  A registry-based randomised trial comparing an SGLT2 inhibitor and metformin as standard treatment of early stage type 2 diabetes (SMARTEST): Rationale, design and protocol. , 2021, Journal of diabetes and its complications.

[5]  J. McGill,et al.  Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetes , 2021, JAMA internal medicine.

[6]  S. Schneeweiss,et al.  Comparative effectiveness and safety of sodium‐glucose cotransporter‐2 inhibitors versus metformin in patients with type 2 diabetes: An observational study using data from routine care , 2021, Diabetes, obesity & metabolism.

[7]  S. Schneeweiss,et al.  Trends in First-Line Glucose-Lowering Drug Use in Adults With Type 2 Diabetes in Light of Emerging Evidence for SGLT-2i and GLP-1RA , 2021, Diabetes Care.

[8]  S. Schneeweiss,et al.  Comparative Effectiveness and Safety of Sodium–Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults , 2021, Diabetes Care.

[9]  9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021. , 2020, Diabetes care.

[10]  S. Schneeweiss,et al.  Emulating Randomized Clinical Trials with Nonrandomized Real-World Evidence Studies: First Results from the RCT DUPLICATE Initiative. , 2020, Circulation.

[11]  Shao‐Wei Chen,et al.  Sodium-glucose cotransporter 2 inhibitor versus metformin as first-line therapy in patients with type 2 diabetes mellitus: a multi-institution database study , 2020, Cardiovascular Diabetology.

[12]  C. Cannon,et al.  Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes , 2020, JAMA cardiology.

[13]  F. Giorgino,et al.  Cardiovascular protection with sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes: Does it apply to all patients? , 2020, Diabetes, obesity & metabolism.

[14]  Yong Chen,et al.  Fixed-effects model: the most convincing model for meta-analysis with few studies , 2020, 2002.04211.

[15]  G. Filippatos,et al.  2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. , 2020, European heart journal.

[16]  F. Cosentino,et al.  The 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. , 2019, European heart journal.

[17]  S. Schneeweiss,et al.  Using Real-World Data to Predict Findings of an Ongoing Phase IV Cardiovascular Outcome Trial: Cardiovascular Safety of Linagliptin Versus Glimepiride , 2019, Diabetes Care.

[18]  K. Connelly,et al.  Reduction in the incidence of myocardial infarction with sodium–glucose linked cotransporter-2 inhibitors: evident and plausible , 2019, Cardiovascular Diabetology.

[19]  S. Schneeweiss,et al.  Comparative risk of genital infections associated with sodium‐glucose co‐transporter‐2 inhibitors , 2018, Diabetes, obesity & metabolism.

[20]  Geltrude Mingrone,et al.  Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2018, Diabetes Care.

[21]  L. Gürke,et al.  Letter by Tampaki et al Regarding Article, "Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors". , 2018, Circulation research.

[22]  Susan Gruber,et al.  Relative Performance of Propensity Score Matching Strategies for Subgroup Analyses , 2018, American journal of epidemiology.

[23]  S. Schneeweiss,et al.  Claims‐based studies of oral glucose‐lowering medications can achieve balance in critical clinical variables only observed in electronic health records , 2018, Diabetes, obesity & metabolism.

[24]  S. Schneeweiss,et al.  Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study , 2018, British Medical Journal.

[25]  S. Suissa.  Mortality Reduction in EMPA-REG OUTCOME Trial: Beyond the Antidiabetes Effect , 2018, Diabetes Care.

[26]  F. Verbrugge.  Role of SGLT2 Inhibitors in Patients with Diabetes Mellitus and Heart Failure , 2017, Current Heart Failure Reports.

[27]  G. Kaplan,et al.  Systematic review of validated case definitions for diabetes in ICD-9-coded and ICD-10-coded data in adult populations , 2016, BMJ Open.

[28]  James M Robins,et al.  Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available. , 2016, American journal of epidemiology.

[29]  S. Schneeweiss,et al.  Improving therapeutic effectiveness and safety through big healthcare data , 2016, Clinical pharmacology and therapeutics.

[30]  JA Rassen,et al.  Transparency and Reproducibility of Observational Cohort Studies Using Large Healthcare Databases. , 2016, Clinical pharmacology and therapeutics.

[31]  F. Sloan,et al.  Adherence to diabetes guidelines for screening, physical activity and medication and onset of complications and death. , 2015, Journal of diabetes and its complications.

[32]  K. Bennett,et al.  Factors associated with high anticholinergic burden in aging adults with intellectual disabilities:a cross-sectional study , 2015 .

[33]  J. Rassen,et al.  Optimal matching ratios in drug safety surveillance. , 2014, Epidemiology.

[34]  Eric Tchetgen Tchetgen,et al.  The Control Outcome Calibration Approach for Causal Inference With Unobserved Confounding , 2013, American journal of epidemiology.

[35]  J. Steiner,et al.  Initial Antihyperglycemic Drug Therapy Among 241 327 Adults With Newly Identified Diabetes From 2005 Through 2010 , 2013, The Annals of pharmacotherapy.

[36]  P. Nyirjesy,et al.  Genital Mycotic Infections in Patients With Diabetes , 2013, Postgraduate medicine.

[37]  L. Lix,et al.  The validity of administrative data to identify hip fractures is high--a systematic review. , 2013, Journal of clinical epidemiology.

[38]  P. Phisitkul,et al.  Declines in Lower Extremity Amputation in the US Medicare Population, 2000-2010 , 2013, Foot & ankle international.

[39]  N. Skolnik,et al.  Management of Hyperglycemia in Type 2 Diabetes , 2012 .

[40]  Karel G M Moons,et al.  Missing covariate data in clinical research: when and when not to use the missing-indicator method for analysis , 2012, Canadian Medical Association Journal.

[41]  Jerry H. Gurwitz,et al.  A systematic review of validated methods for identifying heart failure using administrative data , 2012, Pharmacoepidemiology and drug safety.

[42]  W. Bobo,et al.  Positive predictive value of automated database records for diabetic ketoacidosis (DKA) in children and youth exposed to antipsychotic drugs or control medications: a tennessee medicaid study , 2011, BMC medical research methodology.

[43]  P. Austin,et al.  Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies , 2010, Pharmaceutical statistics.

[44]  P. Austin.  American Journal of Epidemiology Practice of Epidemiology Statistical Criteria for Selecting the Optimal Number of Untreated Subjects Matched to Each Treated Subject When Using Many-to-one Matching on the Propensity Score , 2022 .

[45]  Sebastian Schneeweiss,et al.  A basic study design for expedited safety signal evaluation based on electronic healthcare data , 2010, Pharmacoepidemiology and drug safety.

[46]  S. Hennessy,et al.  Anti‐Infectives and the Risk of Severe Hypoglycemia in Users of Glipizide or Glyburide , 2010, Clinical pharmacology and therapeutics.

[47]  Sebastian Schneeweiss,et al.  Validation of claims‐based diagnostic and procedure codes for cardiovascular and gastrointestinal serious adverse events in a commercially‐insured population , 2010, Pharmacoepidemiology and drug safety.

[48]  P. Austin.  Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples , 2009, Statistics in medicine.

[49]  Peter C. Austin,et al.  Using the Standardized Difference to Compare the Prevalence of a Binary Variable Between Two Groups in Observational Research , 2009, Commun. Stat. Simul. Comput..

[50]  C. Camargo,et al.  Validation of ICD-9-CM coding algorithm for improved identification of hypoglycemia visits , 2008, BMC endocrine disorders.

[51]  J. Shaw,et al.  Risk of Cardiovascular and All-Cause Mortality in Individuals With Diabetes Mellitus, Impaired Fasting Glucose, and Impaired Glucose Tolerance: The Australian Diabetes, Obesity, and Lifestyle Study (AusDiab) , 2007, Circulation.

[52]  Sushrut S Waikar,et al.  Validity of International Classification of Diseases, Ninth Revision, Clinical Modification Codes for Acute Renal Failure. , 2006, Journal of the American Society of Nephrology : JASN.

[53]  S. Schneeweiss.  Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics , 2006, Pharmacoepidemiology and drug safety.

[54]  U. Misra,et al.  Diabetic neuropathy , 2006, Postgraduate Medical Journal.

[55]  J. Avorn,et al.  A review of uses of health care utilization databases for epidemiologic research on therapeutics. , 2005, Journal of clinical epidemiology.

[56]  Sebastian Schneeweiss,et al.  Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. , 2004, American heart journal.

[57]  Donald R. Miller,et al.  Who has diabetes? Best estimates of diabetes prevalence in the Department of Veterans Affairs based on computerized patient data. , 2004, Diabetes care.

[58]  W. Longstreth,et al.  Validating Administrative Data in Stroke Research , 2002, Stroke.

[59]  J. Avorn,et al.  Paradoxical Relations of Drug Treatment with Mortality in Older Persons , 2001, Epidemiology.

[60]  R. Holman,et al.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.

[61]  Donald Rubin,et al.  Estimating Causal Effects from Large Data Sets Using Propensity Scores , 1997, Annals of Internal Medicine.

[62]  W. Ray,et al.  Identification of fractures from computerized Medicare files. , 1992, Journal of clinical epidemiology.

[63]  Louette R. Johnson Lutjens.  Research , 2006 .

[64]  D.,et al.  Regression Models and Life-Tables , 2022 .